Real-World Drug-Coated Balloon Angioplasty in Coronary Artery Disease
Official title: Real-World Outcomes of Drug-Coated Balloon Angioplasty in Coronary Artery Disease: A Multicenter Ambispective Cohort Study
Run by Hospital Arnau de Vilanova · NCT07875088 · Data updated 2026-11-12
This registry tests how drug-coated balloons perform in everyday clinical practice for adults with coronary artery disease undergoing PCI.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 2000 (estimated) |
| Sponsor | Hospital Arnau de Vilanova Academic / other |
| Locations | 5 sites (Mexico City, Mexico City and 4 other locations) |
| Status | Recruiting |
| Started | October 16, 2026 |
| Main results expected | November 2029 |
| Study ends | November 2030 |
| Registry record updated | October 20, 2026 |
| Trial ID | NCT07875088 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 years or older undergoing PCI at participating centers with at least one coronary DCB planned or used during the index procedure.
✕Probably not a fit
Patients for whom a DCB strategy is never planned or used, or whose data are incomplete, may not derive benefit from the findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The RW-DCB is an investigator-led, multicenter observational registry collecting real-world data on the use of drug-coated balloons during percutaneous coronary intervention. It includes consecutive adults where a DCB strategy is planned or attempted, regardless of presentation or lesion type, and regardless of whether the procedure is completed as planned. Data will capture the full intended DCB strategy, including cases where delivery fails, bailouts occur, or strategy changes to another device or therapy are made. Information is collected retrospectively for procedures from 2022 onward and prospectively at each site, using a pseudonymized patient identifier to link procedures, lesions, devices, and follow-up. The study aims to describe the practicality and limitations of DCB use in an all-comer population, including planned hybrid treatments and bailout scenarios.
Why it matters
Potential benefit: If successful, the study could clarify how often DCB strategies are feasible in real-world practice and guide improvements in patient selection and procedural planning.
How similar studies have gone: Previous real-world registries have shown mixed outcomes with DCBs across varied populations; this study adds breadth by including all-comer cases and bailout scenarios.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 years or older at the index procedure. * Percutaneous coronary intervention performed at a participating center during its defined study period, in which at least one coronary drug-coated balloon is selected and introduced into the delivery system with intent to treat an epicardial native coronary lesion or a coronary bypass graft lesion. * Source documentation sufficient to identify the index procedure date, patient, target vessel, and intended drug-coated balloon strategy. * All clinical presentations and coronary lesion types are eligible. Exclusion Criteria: * No coronary drug-coated balloon introduced into the delivery system. * Withdrawal of authorization for prospectively collected data, when applicable. Failure to deliver or inflate the intended drug-coated balloon, crossover to another treatment strategy, and incomplete follow-up are not exclusion criteria.
Where it's running
-
Instituto Nacional de Cardiología Ignacio Chávez
Mexico City, Mexico City, Mexico Recruiting -
Hospital Universitari Son Espases
Palma de Mallorca, Illes Baleares, Spain Recruiting -
Hospital Universitari Arnau de Vilanova de Lleida
Lleida, Lleida, Spain Recruiting -
Hospital Universitario Puerta de Hierro Majadahonda
Majadahonda, Madrid, Spain Recruiting -
Hospital Universitario de Navarra
Pamplona, Navarre, Spain Recruiting
Study contacts
- Principal investigator: Kristian Rivera, MD, PhD — Hospital Universitari Arnau de Vilanova de Lleida
- Study coordinator: Kristian Rivera, MD, PhD
- Email: psrivera.lleida.ics@gencat.cat
- Phone: 973705273
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
μFR-guided Drug-Coated Balloon Angioplasty vs Angiography-guided Angioplasty in Coronary Artery Disease
This trial tests whether using computational μFR guidance during drug-coated balloon angioplasty is better than standard angiography guidance for people with de novo coronary artery lesions.
-
Gastric Ultrasound Before CABG to See if Heart Function Changes Stomach Contents
This study checks whether people with weaker heart function before elective CABG have different stomach contents seen on ultrasound.
-
Can preoperative photon-counting CT help predict heart recovery after bypass surgery?
This observational study tests whether a preoperative photon-counting CT can help predict heart function 3 months after coronary bypass surgery in adults with coronary artery disease.
-
Predicting vasopressor needs after anesthesia in elective on-pump CABG using dynamic arterial elastance
This study tests whether EaDyn measured after induction can help predict which patients will need vasopressors during elective on-pump CABG.
-
Intraoperative Pulse Pressure Variation and Postoperative Lactate Clearance in CABG Patients
This study tests whether the amount a patient’s pulse pressure varies during surgery relates to how quickly lactate levels drop after CABG.
-
AI-powered ECG to help diagnose and predict outcomes in heart disease
Researchers test an AI-enhanced ECG to help diagnose and predict outcomes for people with cardiovascular diseases.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.